Abstract
Vulvovaginal candidiasis (VVC) is a global health problem affecting 75% of women at least once in their lifetime. Here we examined the epidemiology of VVC in a patient cohort to identify the causative organisms associated with VVC. Biofilm-forming capacity and antifungal sensitivity profiles were also assessed. We report a shifting prevalence of Candida species with heterogeneous biofilm-forming capacity, which is associated with altered antifungal drug sensitivity.
| Original language | English |
|---|---|
| Article number | e01065-17 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 61 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sept 2017 |
| Externally published | Yes |
Keywords
- Antifungal Agents/therapeutic use
- Biofilms/drug effects
- Candida albicans/drug effects
- Candida glabrata/drug effects
- Candida parapsilosis/drug effects
- Candida tropicalis/drug effects
- Candidiasis, Vulvovaginal/drug therapy
- Drug Resistance, Fungal
- Female
- Fluconazole/therapeutic use
- Humans
- Microbial Sensitivity Tests
- Vaginal Smears
- Vulvovaginal candidiasis
- Fluconazole
- Candida
- Biofilm
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
Documents and Links
- Sherry, L. et al (2017) Biofilms formed by isolates from recurrent vulvovaginal candidiasis 2 patients are heterogeneous and insensitive to fluconazole
Published by American Society for Microbiology.Copyright © 2017 American Society for Microbiology.